Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

scientific article published in January 2006

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IJC.21271
P698PubMed publication ID16052537
P5875ResearchGate publication ID7692358

P50authorHarvey I PassQ51800337
P2093author name stringAnil Wali
James F Eliason
Joseph F Cortese
Ashok L Gowda
Richard B Everson
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectadenocarcinomaQ356033
P1104number of pages2
P304page(s)521-522
P577publication date2006-01-01
P1433published inInternational Journal of CancerQ332492
P1476titleCommon EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma
P478volume118

Reverse relations

cites work (P2860)
Q28395184DNA copy number gains in malignant pleural mesothelioma
Q37400550Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
Q54538613Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.
Q33760654Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib
Q37449036Future developments in the management of malignant pleural mesothelioma
Q34293068Investigational approaches for mesothelioma
Q37529848Malignant pleural mesothelioma: current treatments and emerging drugs.
Q38019747Malignant pleural mesothelioma: from the bench to the bedside.
Q43797861Mesothelioma: closer to the target?
Q36889671Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
Q35042668New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials
Q39377749Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors
Q37873380Review on clinical trials of targeted treatments in malignant mesothelioma
Q37260408Systemic treatments for mesothelioma: standard and novel
Q37734455Translational therapies for malignant pleural mesothelioma.
Q36755500Update on the molecular biology of malignant mesothelioma

Search more.